The discussion of Microcyn Technology relates to products that have not been cleared by the U.S. Food and Drug administration. Sodium hypochlorite and hypochlorous acid in FDA cleared products are present as preservatives to reduce/prevent the growth of microorganisms within the solution/gel. The effects of FDA-cleared products have not been clinically evaluated.

The investor pages that follow are your resource for financial information about Oculus Innovative Sciences, Inc.. In this section you will find information about our current and historical share price, SEC filings and frequently asked questions as well as forms to request additional information.

Mar 26, 2012
CEO, Hoji Alimi, BioMedReports Video Interview

Investor Presentation ( 1.9MB)

Recent Releases

May 11, 2012
Oculus Innovative Sciences Prepares to Initiate Clinical Study for Use of Microcyn® Hydrogel in Management of Scars Based Upon FDA-Reviewed Protocol

May 9, 2012
Oculus Innovative Sciences Microcyn® Technology to be Showcased at the Columbia University 10th Annual Innovations in Complex Vascular & Endovascular Interventions in New York City on May 10-11, 2012

Apr 26, 2012
Oculus Innovative Sciences' Microcyn Acute Care Products Showcased at Symposium on Advanced Wound Care in Atlanta

more »

Forward-Looking Statements
This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to our product development, success of clinical trials, obtaining the requisite regulatory approvals, market acceptance of our product, our ability to protect our intellectual property and future financial results. For a discussion of other factors that may cause Oculus’ actual results to differ from those projected, expressed or implied by the forward looking statements, please refer to the Company's Registration Statement on Form S-1 as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.